Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Varenicline Nasal Spray Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

NCT05082974
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Vance Thompson Vision ND
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT04036292
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 27, 2026, 3:16 PM EDT
Recruiting Phase 4 Interventional

Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment

NCT07606625
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
Varenicline 0.03Mg/Spray Nasal Soln
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Results available

Nasal Spray Study in Sjogren's Dry Eye Disease

NCT05700422
View directory record Official record
Conditions
Sjogren's Syndrome, Dry Eye
Interventions
Varenicline Nasal Spray
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 27, 2026, 3:16 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

NCT05045508
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) Nasal Spray
Drug
Lead sponsor
Brandon Baartman
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

NCT05161208
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) Nasal Spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03636061
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Not applicable Interventional

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NCT04694846
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

NCT04957758
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 27, 2026, 3:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg

NCT07705893
View directory record Official record
Conditions
Dry Eye
Interventions
Tyrvaya
Drug
Lead sponsor
Ocular Aesthetics, LLC dba Ocular Clinical Trials
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Results available

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

NCT04490057
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler, Varenicline or bupropion, Contingency Management
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Bridgeport, Connecticut • New Haven, Connecticut • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

NCT04072146
View directory record Official record
Conditions
Healthy Subjects
Interventions
Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg, OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2022 · Synced Sep 27, 2026, 3:16 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

NCT05136924
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray
Drug · Other
Lead sponsor
Vance Thompson Vision - MT
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 27, 2026, 3:16 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice

NCT01850589
View directory record Official record
Conditions
Smoking Cessation
Interventions
Aggressive Therapy
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 27, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care

NCT03670316
View directory record Official record
Conditions
HIV, AIDS, Smoking Cessation
Interventions
Algorithm Treatment, Quitline only
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 27, 2026, 3:16 PM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients

NCT02147132
View directory record Official record
Conditions
Cigarette Smoking, Methadone Maintenance
Interventions
Nicotine Nasal Spray, Varenicline, Placebo Nasal Spray, Placebo Varenicline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 27, 2026, 3:16 PM EDT